VivoSim Labs (FRA:4OR) Non Operating Income: €0.00 Mil (TTM As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
38 GF Score
Price €3.49
GF Value €11.36
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Non Operating Income?

VivoSim Labs FRA:4OR 38 Non Operating Income is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 38/100 and a GF Value™ of €11.36. The stock has 4 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. VivoSim Labs's Non Operating Income for the three months ended in Dec. 2025 was €0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

VivoSim Labs Non Operating Income Related Terms

VivoSim Labs Non Operating Income Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Non Operating Income Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 0.02 0.02 0.01 9.25

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:4OR
38GF Score
VivoSim Labs Inc FRA:4OR
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of €0.00 Mil mean?
VivoSim Labs (FRA:4OR) has a Non Operating Income of €0.00 Mil as of Dec. 2025. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on VivoSim Labs and its competitors.
Is VivoSim Labs' Non Operating Income too high?
VivoSim Labs' current Non Operating Income is €0.00 Mil. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Non Operating Income compare to SLXN and CDT?
VivoSim Labs' Non Operating Income of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Non Operating Income is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Non Operating Income of €0.00 Mil. The stock's GF Value™ is €11.36, compared to a current price of €3.49 — trading 69.3% below its estimated fair value. The current Non Operating Income is €0.00 Mil. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Non Operating Income is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 69.3% below its estimated GF Value™ of €11.36.

Key valuation signals for FRA:4OR:

  • Non Operating Income: €0.00 Mil
  • GF Value™: €11.36 vs. price of €3.49 (69.3% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score

Get the complete analysis for FRA:4OR

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€11.36
GF Value